Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis

Published:2021-10 Issue:10 Volume:27 Page:873.e1-873.e13
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Bewersdorf Jan Philipp,Sheth Amar H.,Vetsa Shaurey,Grimshaw Alyssa,Giri Smith,Podoltsev Nikolai A.,Gowda Lohith,Tamari Roni,Tallman Martin S.,Rampal Raajit K.,Zeidan Amer M.,Stahl Maximilian

Funder

ASCO

National Cancer Institute

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference75 articles.

1. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis;Tefferi;Blood,2014

2. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map;Shallis;Blood Rev,2020

3. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms;Vainchenker;Blood,2017

4. Myelofibrosis biology and contemporary management;Gangat;Br J Haematol,2020

5. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis;Guglielmelli;J Clin Oncol,2018

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transplant Outcomes in Myelofibrosis: Impact of Donor Type [Cord Blood Grafts Supported by CD34+ selected Cells (Haplo-Cord) vs Matched Donors];Transplantation and Cellular Therapy;2024-09

2. JAK2 V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes;Blood Advances;2023-12-14

3. Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT;Bone Marrow Transplantation;2023-09-07

4. Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature;Transplantation and Cellular Therapy;2023-07

5. Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT;2023-06-29